Baker Brothers Advisors - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.

Quarter-by-quarter ownership
Baker Brothers Advisors ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$47,284,022
+10.1%
2,292,003
+57.5%
0.27%
+9.6%
Q2 2023$42,946,552
+71.2%
1,455,322
+33.7%
0.25%
+83.1%
Q1 2023$25,084,524
-17.2%
1,088,7380.0%0.14%
-25.3%
Q4 2022$30,277,804
+67.6%
1,088,738
+84.9%
0.18%
+54.2%
Q3 2022$18,068,000
+4.3%
588,7380.0%0.12%
+20.4%
Q2 2022$17,327,000
+506.9%
588,738
+563.5%
0.10%
+512.5%
Q1 2022$2,855,000
-27.9%
88,7380.0%0.02%
-15.8%
Q4 2021$3,958,000
-11.6%
88,7380.0%0.02%
-5.0%
Q3 2021$4,477,000
-35.7%
88,7380.0%0.02%
-35.5%
Q2 2021$6,961,000
+37.4%
88,7380.0%0.03%
+40.9%
Q1 2021$5,067,000
-31.8%
88,7380.0%0.02%
-21.4%
Q4 2020$7,433,000
+108.7%
88,738
-10.7%
0.03%
+100.0%
Q3 2020$3,562,000
+40.5%
99,400
-5.2%
0.01%
+27.3%
Q2 2020$2,536,000
+38.1%
104,9000.0%0.01%0.0%
Q1 2020$1,837,000104,9000.01%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Crestline Management, LP 5,960,732$122,969,90114.32%
ARCH Venture Management, LLC 693,749$14,312,0429.30%
Flagship Pioneering Inc. 2,619,968$54,049,9403.92%
Casdin Capital, LLC 1,300,000$26,819,0002.97%
Yiheng Capital Management, L.P. 1,150,684$23,738,6111.21%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 154,000$3,172,4001.07%
SECTORAL ASSET MANAGEMENT INC 254,941$5,259,4331.02%
Temasek Holdings (Private) Ltd 6,895,992$142,264,3150.85%
Clarius Group, LLC 378,262$7,803,5450.74%
Artal Group S.A. 802,899$16,5640.71%
View complete list of DENALI THERAPEUTICS INC shareholders